相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。RET/PTC and PAX8/PPAR chromosomal rearrangements in post-Chernobyl thyroid cancer and their association with iodine-131 radiation dose and other characteristics
Rebecca J. Leeman-Neill et al.
CANCER (2013)
Molecular pathogenesis and mechanisms of thyroid cancer
Mingzhao Xing
NATURE REVIEWS CANCER (2013)
Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants
Johannes M. Heuckmann et al.
CLINICAL CANCER RESEARCH (2012)
CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant
Hiroshi Sakamoto et al.
CANCER CELL (2011)
Differential cytotoxic effects of atorvastatin in human hepatocellular carcinoma and pancreatic adenocarcinoma cells
Maria B. Lai et al.
CANCER RESEARCH (2011)
Integrative identification of stochastically activated signaling sub-networks in individual cancer cells
Iadevaia Sergio et al.
CANCER RESEARCH (2011)
Massive Genomic Rearrangement Acquired in a Single Catastrophic Event during Cancer Development
Philip J. Stephens et al.
CELL (2011)
ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors
Johannes M. Heuckmann et al.
CLINICAL CANCER RESEARCH (2011)
Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
J. Jean Cui et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Molecular genetics and diagnosis of thyroid cancer
Yuri E. Nikiforov et al.
NATURE REVIEWS ENDOCRINOLOGY (2011)
Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK
Ryohei Katayama et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain
Christian C. Lee et al.
BIOCHEMICAL JOURNAL (2010)
Anaplastic Thyroid Carcinoma: Pathogenesis and Emerging Therapies
R. C. Smallridge et al.
CLINICAL ONCOLOGY (2010)
Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer
Eunice L. Kwak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
RAS Mutations Are the Predominant Molecular Alteration in Poorly Differentiated Thyroid Carcinomas and Bear Prognostic Impact
Marco Volante et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Targeted next-generation sequencing of a cancer transcriptome enhances detection of sequence variants and novel fusion transcripts
Joshua Z. Levin et al.
GENOME BIOLOGY (2009)
Oncogenic mutations of ALK kinase in neuroblastoma
Yuyan Chen et al.
NATURE (2008)
Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma
James G. Christensen et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
Manabu Soda et al.
NATURE (2007)
Unique substrate specificity of anaplastic lymphoma kinase (ALK): Development of phosphoacceptor peptides for the assay of ALK activity
A Donella-Deana et al.
BIOCHEMISTRY (2005)
Anaplastic thyroid carcinoma - Treatment outcome and prognostic factors
E Kebebew et al.
CANCER (2005)
The development of imatinib as a therapeutic agent for chronic myeloid leukemia
M Deininger et al.
BLOOD (2005)
Differential effects of X-ALK fusion proteins on proliferation, transformation, and invasion properties of NIH3T3 cells
F Armstrong et al.
ONCOGENE (2004)
RET/PTC rearrangement in thyroid tumors
YE Nikiforov
ENDOCRINE PATHOLOGY (2002)
Recurrent chromosome aberrations in cancer
F Mitelman
MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH (2000)
分享论文
